Corporate information

Official name
Aderis Pharmaceuticals Incorporated
Registration country

Company type

Novel small molecule, receptor-specific therapeutics company for the treatment of central nervous system, cardiovascular and renal diseases.

Funding rounds

Series D USD 45,000,000


USD 45,000,000 ( )

Profile Country Notes
Paladin Capital Group Private equity firm Initial investment. Led the round.
China Development Industrial Bank (CDIB) Private development financial institution in Taiwan. Initial investment.
International Biotechnology Trust PLC Initial investment.
MDS Capital Corp Initial investment.
NeoMed Management AS Initial investment.
Perseus-Soros BioPharmaceutical Fund LP Initial investment.
Sanderling Ventures Initial investment.
Schroder Ventures KK Initial investment.
Singapore Bio-Innovations Initial investment.
Temasek Holdings (Pte) Ltd Singapore's sovereign wealth fund. Initial investment.

Profile Country Notes
Lumira Capital Investment Management Inc (Lumira Ventures) Canadian healthcare and life sciences venture capital firm. Initial investment.

Profile Country Notes
Alliance Technology Ventures (ATV) Initial investment.

Profile Country Notes
Sanderling Ventures Initial investment.

Profile Country Notes
Bio*One Capital Pte Ltd Initial investment.

Profile Country Notes
SV Life Sciences Advisers LLP Initial investment.

Profile Country Notes
SV Life Sciences Advisers Inc Initial investment.


Investment activity status
Active investor

Current team

Past employees

Selected Products / Customers

Financials